Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: stocktwits
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 22.160
Low
16.50
Averages
32.95
High
60.00
Current: 22.160
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
See More
Hims & Hers Appoints New Chief Communications Officer
- Executive Appointment: Hims & Hers Health, Inc. has appointed Kathryn Beiser as Chief Communications Officer, responsible for leading external and internal communications as the company enters a new phase of domestic and international growth, highlighting its commitment to brand development.
- Extensive Experience: Beiser has served as Chief Communications Officer at Eli Lilly and Kaiser Permanente, bringing expertise in launching and elevating corporate brands in highly regulated industries, which is expected to strategically enhance Hims & Hers' brand presence.
- Leadership Vision: CEO Andrew Dudum stated that Beiser will play a crucial role in the company's ambition to become the most trusted brand globally, emphasizing that her industry experience and communication expertise will help bring the company's story to life.
- Customer Focus: Beiser expressed excitement about the opportunity to work with the Hims & Hers team, indicating the company's commitment to a customer-first approach, aiming to help more individuals achieve health and happiness through personalized care.
See More
HIMS & HERS APPOINTS KATHRYN BEISER AS CHIEF COMMUNICATIONS OFFICER
- New Appointment: Kathryn Beiser has been appointed as the Chief Communications Officer.
- Role Overview: As Chief Communications Officer, Beiser will oversee the organization's communication strategies and initiatives.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Stake Sale Overview: On February 17, 2026, BLKBRD Asset Management disclosed it sold all 318,666 shares of Hims & Hers Health, with an estimated transaction value of $18.07 million, reflecting a complete exit from its position during the fourth quarter.
- Impact on Asset Management: This sale reduced Hims & Hers' stake from 5% to 0%, indicating a significant loss of confidence from BLKBRD, which could negatively influence market perceptions of Hims & Hers.
- Stock Performance: As of February 16, 2026, Hims & Hers shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points, highlighting severe competitive challenges.
- Future Outlook: Although Hims & Hers recently announced a new partnership with Novo Nordisk that may provide a short-term stock rebound, ongoing market pressures and competitive challenges suggest that investors should carefully assess the company's long-term prospects.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Complete Exit: On February 17, 2026, BLKBRD Asset Management disclosed it fully exited its position in Hims & Hers Health by selling 318,666 shares, with an estimated trade value of $18.07 million, resulting in a 24.3% drop in the fund's quarterly average assets under management (AUM).
- Value Decline: The liquidation left Hims & Hers Health with a net position value of zero, previously accounting for 5.0% of the fund's AUM, indicating a complete loss of confidence in the stock by the fund.
- Market Reaction: Hims & Hers' stock has been in freefall since last June, plummeting from a historical high of $64 to around $15, primarily due to Novo Nordisk terminating its partnership and suing the company, which negatively impacted market expectations for its future.
- New Partnership Opportunity: Despite these challenges, Hims & Hers announced a new partnership with Novo Nordisk on March 10, 2026, to offer its weight-loss drugs Ozempic and Wegovy, leading to a 6% stock price increase and providing investors with a chance to reassess the company's prospects.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
See More
Hims & Hers Appoints New Chief Communications Officer
- Executive Appointment: Hims & Hers Health, Inc. has appointed Kathryn Beiser as Chief Communications Officer, responsible for leading external and internal communications as the company enters a new phase of domestic and international growth, highlighting its commitment to brand development.
- Extensive Experience: Beiser has served as Chief Communications Officer at Eli Lilly and Kaiser Permanente, bringing expertise in launching and elevating corporate brands in highly regulated industries, which is expected to strategically enhance Hims & Hers' brand presence.
- Leadership Vision: CEO Andrew Dudum stated that Beiser will play a crucial role in the company's ambition to become the most trusted brand globally, emphasizing that her industry experience and communication expertise will help bring the company's story to life.
- Customer Focus: Beiser expressed excitement about the opportunity to work with the Hims & Hers team, indicating the company's commitment to a customer-first approach, aiming to help more individuals achieve health and happiness through personalized care.
See More
HIMS & HERS APPOINTS KATHRYN BEISER AS CHIEF COMMUNICATIONS OFFICER
- New Appointment: Kathryn Beiser has been appointed as the Chief Communications Officer.
- Role Overview: As Chief Communications Officer, Beiser will oversee the organization's communication strategies and initiatives.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Stake Sale Overview: On February 17, 2026, BLKBRD Asset Management disclosed it sold all 318,666 shares of Hims & Hers Health, with an estimated transaction value of $18.07 million, reflecting a complete exit from its position during the fourth quarter.
- Impact on Asset Management: This sale reduced Hims & Hers' stake from 5% to 0%, indicating a significant loss of confidence from BLKBRD, which could negatively influence market perceptions of Hims & Hers.
- Stock Performance: As of February 16, 2026, Hims & Hers shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points, highlighting severe competitive challenges.
- Future Outlook: Although Hims & Hers recently announced a new partnership with Novo Nordisk that may provide a short-term stock rebound, ongoing market pressures and competitive challenges suggest that investors should carefully assess the company's long-term prospects.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Complete Exit: On February 17, 2026, BLKBRD Asset Management disclosed it fully exited its position in Hims & Hers Health by selling 318,666 shares, with an estimated trade value of $18.07 million, resulting in a 24.3% drop in the fund's quarterly average assets under management (AUM).
- Value Decline: The liquidation left Hims & Hers Health with a net position value of zero, previously accounting for 5.0% of the fund's AUM, indicating a complete loss of confidence in the stock by the fund.
- Market Reaction: Hims & Hers' stock has been in freefall since last June, plummeting from a historical high of $64 to around $15, primarily due to Novo Nordisk terminating its partnership and suing the company, which negatively impacted market expectations for its future.
- New Partnership Opportunity: Despite these challenges, Hims & Hers announced a new partnership with Novo Nordisk on March 10, 2026, to offer its weight-loss drugs Ozempic and Wegovy, leading to a 6% stock price increase and providing investors with a chance to reassess the company's prospects.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
